FindTrial
Sign In

ATX-101

DRUG9 trials

Sponsors

Kythera Biopharmaceuticals, Northwestern University, Benjamin Izar, Allay Therapeutics, Inc.

Conditions

Acute Postoperative PainCharacteristics of Subcutaneous FatEfficacyHealthyLeiomyosarcomaLiposarcomaModerate to Severe Convexity of Submental FatSafety

Phase 1

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101
CompletedNCT00618709
Kythera BiopharmaceuticalsHealthy
Start: 2008-01-31End: 2009-01-31Updated: 2014-05-30
ATX-101 Abdominoplasty
CompletedNCT00835952
Kythera BiopharmaceuticalsCharacteristics of Subcutaneous Fat
Start: 2008-11-30End: 2009-04-30Target: 14Updated: 2010-01-27
Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue
CompletedNCT01319916
Kythera BiopharmaceuticalsHealthy
Start: 2010-12-31End: 2011-01-31Updated: 2011-03-22
To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101
CompletedNCT01462786
Kythera BiopharmaceuticalsHealthy
Start: 2011-10-31End: 2011-12-31Updated: 2016-05-06

Phase 2

ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
TerminatedNCT05116683
Benjamin IzarLeiomyosarcoma, Liposarcoma
Start: 2022-01-11End: 2022-10-27Updated: 2023-12-06
Study Assessing Pain Relief After Replacement of the Knee
TerminatedNCT05260008
Allay Therapeutics, Inc.Acute Postoperative Pain
Start: 2022-06-07End: 2024-01-15Updated: 2025-08-14

Phase 3

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age
CompletedNCT02123134
Kythera BiopharmaceuticalsEfficacy, Moderate to Severe Convexity of Submental Fat, Safety
Start: 2014-04-30End: 2015-09-30Updated: 2020-02-17
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
CompletedNCT02163902
Kythera BiopharmaceuticalsHealthy, Submental Fat
Start: 2013-12-31End: 2016-08-31Updated: 2020-02-17

Unknown Phase

Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for Upper Back Fat
TerminatedNCT03284034
Northwestern UniversityUpper Back Fat
Start: 2017-11-27End: 2020-06-08Updated: 2025-05-06

Related Papers

A phase II study, with a safety lead-in, to evaluate ATX-101, a peptide drug targeting PCNA, in advanced dedifferentiated liposarcoma and leiomyosarcoma.
Journal of Clinical Oncology2022-06-015 citations
Improvements in Submental Contour up to 3 Years After ATX-101: Efficacy and Safety Follow-Up of the Phase 3 REFINE Trials
Aesthetic Surgery Journal2021-02-2213 citations